Fluciclovine (Axumin) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid (also known as Fluciclovine (18F)) was approved under brand name AXUMIN as a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence. Besides, this radioactive compound is used in patients with cervical, ovarian epithelial or endometrial cancers. Fluciclovine F 18 is a synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells, but as was shown, this compound has a higher affinity for ASCT2 in comparison with other transporters.   NCATS

Chemistry

  • SMILES: C[C@@]1(F)C[C@@](N)(C1)C(=O)O
  • InChIKey: ILMJJAKSEOUEPX-IZLXSQMJSA-N
  • Mol. Mass: 147.15
  • ALogP: 0.29
  • ChEMBL Molecules:
    fluciclovine  
    fluciclovine f18  
More Chemistry

Pharmacology

  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

18f | (18f)facbc | 18f facbc | 18f-facbc | 18f-fluciclovine | (18f)ge-148 | 1-amino-3-fluorocyclobutane-1-carboxylic acid | (1r,3r)-1-amino-3(18f)fluorocyclobutane-1-carboxylic acid | anti-(18f)facbc | anti-1-amino-3-(18f)fluorocyclobutane-1-carboxylic acid | axumin | cyclobutanecarboxylic acid, 1-amino-3-(fluoro-18f)-, trans- | f(18)1-amino-3-fluorocyclobutane-1-carboxylic acid | f(18)-facbc | facbc | facbc f-18 | f-facbc | fluciclovine | fluciclovine (18f) | fluciclovine f18 | fluciclovine f 18 | fluciclovine f-18 | ge-148 (18f) | ge-148 f-18 | nmk36 | nmk 36 | nmk-36 | nmk36 cpd

Organizations (36)

Research & Development (36)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (21)

Approved Indications (4)


 

Carcinoma, Ovarian Epithelial

Endometrial Neoplasms

Prostatic Neoplasms (approved 2016)

Uterine Cervical Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Brain Neoplasms (Phase 3)

Breast Neoplasms (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 4)

Carcinoma, Transitional Cell (Phase 1)

Endometrial Neoplasms (Phase 4)

Glioblastoma (Phase 2)

Glioma (Early Phase 1)

Graft Rejection (Phase 1)

Lung Neoplasms (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Pancreatitis, Graft (Early Phase 1)

Prostatic Neoplasms (Phase 4)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Testicular Diseases (Phase 2)

Testicular Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Early Phase 1)

Uterine Cervical Neoplasms (Phase 4)

Uterine Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 48
  • # of Trial Organizations: 36

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue